Epigenetic changes as prognostic predictors in endometrial carcinomas

Epigenetics. 2017 Jan 2;12(1):19-26. doi: 10.1080/15592294.2016.1252891. Epub 2016 Nov 22.

Abstract

Endometrial carcinoma is one of the most frequent gynecological malignancies of the female. The diagnostic and prognostic markers for the high-risk subgroups with unfavorable prognosis are under intense debate worldwide, and, therefore, the aim of this study was to identify new potential DNA methylation markers for the high-risk groups. We used the Illumina Infinium HumanMethylation450 BeadChip to analyze the DNA methylation pattern and investigated its association with clinicopathological features important for defining the high-risk (FIGO-grade 3) and low-risk (FIGO-grade 1) groups of patients with endometrial cancer (n = 31 and n = 39, respectively). We identified specific DNA methylation signature in high-risk endometrial tumors, and potential molecular biomarker genes (TBX2, CHST11, and NID2) associated with unfavorable clinical predictive and prognostic factors.

Keywords: DNA methylation; FIGO grade; endometrial cancer; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / genetics*
  • Cohort Studies
  • CpG Islands
  • DNA Methylation
  • Endometrial Neoplasms / diagnosis*
  • Endometrial Neoplasms / genetics*
  • Endometrial Neoplasms / mortality
  • Endometrial Neoplasms / pathology
  • Epigenesis, Genetic*
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Prognosis
  • Survival Analysis

Substances

  • Biomarkers, Tumor